https://www.has-sante.fr/jcms/p_3368313/fr/breyanzi-lisocabtagene-maraleucel-liso-cel-ldgcb 2022 false false false France treatment outcome insurance, health, reimbursement Lisocabtagene Maraleucel lymphoma, large B-Cell, diffuse adult High Grade B-Cell Lymphoma Recurrent Primary Mediastinal Large B-Cell Lymphoma Refractory Primary Mediastinal Large B-Cell Lymphoma guidelines for drug use Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal
product form) continuity of patient care immunotherapy, adoptive infusions, intravenous lisocabtagene maraleucel evaluation of the transparency committee